---
title: "Ozempic (semaglutide) in type 2 diabetes: Clinical trials questions"
description: "Clinical trials questions on Ozempic (semaglutide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Cardiovascular outcomes, and Kidney outcomes. Questions: How much weight do adults lose on Ozempic in type 2 diabetes trials? How much did Ozempic lower A1C as monotherapy compared with placebo? Ozempic vs sitagliptin (Januvia): how much did each lower A1C? Ozempic vs exenatide ER (Bydureon): how much did each lower A1C? 11 further questions follow. 15 questions quoted from 10 sources."
canonical: "https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ozempic (semaglutide) in type 2 diabetes: Clinical trials questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Ozempic](https://www.novo-pi.com/ozempic.pdf), [Ozempic tablets](https://www.novo-pi.com/ozempictablets.pdf)

## Study results

<a id="ozempic-weight-loss-trials"></a>

### How much weight do adults lose on Ozempic in type 2 diabetes trials?

> “Ozempic<sup>®</sup> is not indicated for weight loss.”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=is%20not%20indicated%20for%20weight%20loss.)

> “Weight loss was a secondary endpoint in clinical trials. In clinical trials examining glycemic control, adults lost an average of 7 lb to 14 lb with Ozempic<sup>®</sup> injection across doses and 4.8 lb to 9.7 lb with semaglutide tablets 7 mg and 14 mg.<sup>1,2</sup>”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=loss%20was%20a%20secondary%20endpoint,tablets%207%20mg%20and%2014)

> “Ozempic<sup>®</sup> tablets 1.5 mg, 4 mg, and 9 mg are an updated formulation with increased bioavailability. This updated formulation is established with comparable mean exposure and peak concentration. The safety and effectiveness of Ozempic<sup>®</sup> tablets were established through adequate and well-controlled studies of semaglutide tablets 3 mg, 7 mg, and 14 mg.<sup>1,3</sup>”

Source: [OZEMPIC: GLP-1 RA for T2D, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic.html#:~:text=tablets%201.5%20mg%2C%204%20mg%2C,mg%2C%207%20mg%2C%20and%2014)

<a id="ozempic-monotherapy-a1c"></a>

### How much did Ozempic lower A1C as monotherapy compared with placebo?

Applies to: Type 2 diabetes in adults; Ozempic injection (pen)

> “In a 30-week double-blind trial (NCT02054897), 388 patients with type 2 diabetes mellitus 
> inadequately controlled with diet and exercise were randomized to OZEMPIC<sup>®</sup> 0.5 mg or 
> OZEMPIC<sup>®</sup> 1 mg once weekly or placebo. Patients had a mean age of 54 years and 54% were men. 
> The mean duration of type 2 diabetes was 4.2 years, and the mean BMI was 33 kg/m<sup>2</sup>. Overall, 
> 64% were White, 8% were Black or African American, and 21% were Asian; 30% identified as 
> Hispanic or Latino ethnicity.”

Source: [OZEMPIC: Ozempic®, page 6, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=6)

> “Table 3. Results at Week 30 in a Trial of OZEMPIC<sup>®</sup> as Monotherapy in Adult 
> Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and 
> Exercise
> Placebo
> OZEMPIC<sup>®</sup> 0.5 mg
> OZEMPIC<sup>®</sup> 1 mg
> Intent-to-Treat (ITT) Population (N)<sup>a</sup>
> 129
> 128
> 130
> HbA1c (%)
> Baseline (mean)
> 8
> 8.1
> 8.1
> Change at week 30<sup>b</sup>
> -0.1
> -1.4
> -1.6
> Difference from placebo<sup>b</sup> [95% CI]
> -1.2 [-1.5, -0.9]<sup>c</sup>
> -1.4 [-1.7, -1.1]<sup>c</sup>
> Patients (%) achieving HbA1c <7% 
> 28
> 73
> 70”

Source: [OZEMPIC: Ozempic®, page 6, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=6)

> “The mean baseline body weight was 89.1 kg, 89.8 kg, 96.9 kg in the placebo, OZEMPIC<sup>®</sup> 0.5 
> mg, and OZEMPIC<sup>®</sup> 1 mg arms, respectively. The mean changes from baseline to week 30 were 
> -1.2 kg, -3.8 kg and -4.7 kg in the placebo, OZEMPIC<sup>®</sup> 0.5 mg, and OZEMPIC<sup>®</sup> 1 mg arms, 
> respectively. The difference from placebo (95% CI) for OZEMPIC<sup>®</sup> 0.5 mg was -2.6 kg (-3.8, -1.5), 
> and for OZEMPIC<sup>®</sup> 1 mg was -3.5 kg (-4.8, -2.2).”

Source: [OZEMPIC: Ozempic®, page 6, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=6)

Note: Table columns are placebo, OZEMPIC® 0.5 mg, and OZEMPIC® 1 mg, in that order; the difference-from-placebo row lists the 0.5 mg and 1 mg results.

<a id="ozempic-vs-sitagliptin-a1c"></a>

### Ozempic vs sitagliptin (Januvia): how much did each lower A1C?

Applies to: Type 2 diabetes in adults; Ozempic injection (pen)

> “In a 56-week, double-blind trial (NCT01930188), 1231 patients with type 2 diabetes mellitus were 
> randomized to OZEMPIC<sup>®</sup> 0.5 mg once weekly, OZEMPIC<sup>®</sup> 1 mg once weekly, or sitagliptin 100 
> mg once daily, all in combination with metformin (94%) and/or thiazolidinediones (6%). Patients 
> had a mean age of 55 years and 51% were men. The mean duration of type 2 diabetes was 6.6 
> years, and the mean BMI was 32 kg/m<sup>2</sup>. Overall, 68% were White, 5% were Black or African 
> American, and 25% were Asian; 17% identified as Hispanic or Latino ethnicity.”

Source: [OZEMPIC: Ozempic®, page 6, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=6)

> “Table 4. Results at Week 56 in a Trial of OZEMPIC<sup>®</sup> Compared to Sitagliptin in 
> Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin and/
> or Thiazolidinediones
> OZEMPIC<sup>®</sup> 0.5 mg OZEMPIC<sup>®</sup> 1 mg
> Sitagliptin
> Intent-to-Treat (ITT) Population (N)<sup>a</sup>
> 409
> 409
> 407
> HbA1c (%)
> Baseline (mean)
> 8
> 8
> 8.2
> Change at week 56<sup>b</sup>
> -1.3
> -1.5
> -0.7
> Difference from sitagliptin<sup>b</sup> 
> [95% CI]
> -0.6 
> [-0.7, -0.4]<sup>c</sup>
> -0.8
> [-0.9, -0.6]<sup>c</sup>
> Patients (%) achieving HbA1c <7% 
> 66
> 73
> 40”

Source: [OZEMPIC: Ozempic®, page 6, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=6)

> “The mean baseline body weight was 89.9 kg, 89.2 kg, 89.3 kg in the OZEMPIC<sup>®</sup> 0.5 mg, 
> OZEMPIC<sup>®</sup> 1 mg, and sitagliptin arms, respectively. The mean changes from baseline to week 
> 56 were -4.2 kg, -5.5 kg, and -1.7 kg for the OZEMPIC<sup>®</sup> 0.5 mg, OZEMPIC<sup>®</sup> 1 mg, and sitagliptin 
> arms, respectively. The difference from sitagliptin (95% CI) for OZEMPIC<sup>®</sup> 0.5 mg was -2.5 kg 
> (-3.2, -1.8), and for OZEMPIC<sup>®</sup> 1 mg was -3.8 kg (-4.5, -3.1).”

Source: [OZEMPIC: Ozempic®, page 6, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=6)

Note: Table columns are OZEMPIC® 0.5 mg, OZEMPIC® 1 mg, and sitagliptin, in that order; the difference-from-sitagliptin row lists the 0.5 mg and 1 mg results.

<a id="ozempic-vs-exenatide-a1c"></a>

### Ozempic vs exenatide ER (Bydureon): how much did each lower A1C?

Applies to: Type 2 diabetes in adults; Ozempic injection (pen)

> “In a 56-week, open-label trial (NCT01885208), 813 patients with type 2 diabetes mellitus on 
> metformin alone (49%), metformin with sulfonylurea (45%), or other (6%) were randomized to 
> OZEMPIC<sup>®</sup> 1 mg once weekly or exenatide 2 mg once weekly. Patients had a mean age of 57 years 
> and 55% were men. The mean duration of type 2 diabetes was 9 years, and the mean BMI was 34 
> kg/m<sup>2</sup>. Overall, 84% were White, 7% were Black or African American, and 2% were Asian; 24% 
> identified as Hispanic or Latino ethnicity.”

Source: [OZEMPIC: Ozempic®, page 7, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=7)

> “Table 5. Results at Week 56 in a Trial of OZEMPIC<sup>®</sup> Compared to Exenatide 2 mg 
> Once Weekly in Adult Patients with Type 2 Diabetes Mellitus in Combination with 
> Metformin or Metformin with Sulfonylurea
> OZEMPIC<sup>®</sup> 1 mg
> Exenatide ER 2 mg
> Intent-to-Treat (ITT) Population (N)<sup>a</sup>
> 404
> 405
> HbA1c (%)
> Baseline (mean)
> 8.4
> 8.3
> Change at week 56<sup>b</sup>
> -1.4
> -0.9
> Difference from exenatide<sup>b</sup> 
> [95% CI]
> -0.5
> [-0.7, -0.3]<sup>c</sup>
> Patients (%) achieving HbA1c <7% 
> 62
> 40”

Source: [OZEMPIC: Ozempic®, page 7, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=7)

> “The mean baseline body weight was 96.2 kg and 95.4 kg in the OZEMPIC<sup>®</sup> 1 mg and exenatide 
> ER arms, respectively. The mean changes from baseline to week 56 were -4.8 kg and -2 kg in the 
> OZEMPIC<sup>®</sup> 1 mg and exenatide ER arms, respectively. The difference from exenatide ER (95% CI) 
> for OZEMPIC<sup>®</sup> 1 mg was -2.9 kg (-3.6, -2.1).”

Source: [OZEMPIC: Ozempic®, page 7, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=7)

Note: Table columns are OZEMPIC® 1 mg and exenatide ER 2 mg, in that order.

<a id="ozempic-sustain4-a1c"></a>

### Ozempic vs insulin glargine (Lantus): how much did each lower A1C (SUSTAIN 4)?

Applies to: Type 2 diabetes in adults; Ozempic injection (pen)

> “SUSTAIN 4: A 30-week, randomized, open-label, active-controlled trial in 1089 insulin-naïve adult patients on metformin ± sulfonylurea with type 2 diabetes comparing Ozempic<sup>®</sup> injection 0.5 mg and Ozempic<sup>®</sup> injection 1 mg with Lantus<sup>®</sup>.<sup>5</sup>”

Source: [OZEMPIC: A1C & Weight Results, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-pen-a1c-and-weight.html#:~:text=SUSTAIN%204%3A%20A%2030%2Dweek%2C%20randomized%2C,injection%201%20mg%20with)

> “Patients assigned to insulin glargine had a baseline mean HbA1c of 8.1% and were started on a 
> dose of 10 U once daily. Insulin glargine dose adjustments occurred throughout the trial period 
> based on self-measured fasting plasma glucose before breakfast, targeting 71 to <100 mg/dL. In 
> addition, investigators could titrate insulin glargine at their discretion between study visits. Only 
> 26% of patients had been titrated to goal by the primary endpoint at week 30, at which time the 
> mean daily insulin dose was 29 U per day.”

Source: [OZEMPIC: Ozempic®, page 7, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=7)

> “Table 6. Results at Week 30 in a Trial of OZEMPIC<sup>®</sup> Compared to Insulin Glargine 
> in Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin or 
> Metformin with Sulfonylurea
> OZEMPIC<sup>®</sup> 0.5 mg OZEMPIC<sup>®</sup> 1 mg
> Insulin Glargine
> Intent-to-Treat (ITT) Population (N)<sup>a</sup>
> 362
> 360
> 360
> HbA1c (%)
> Baseline (mean)
> 8.1
> 8.2
> 8.1
> Change at week 30<sup>b</sup>
> -1.2
> -1.5
> -0.9
> Difference from insulin glargine<sup>b</sup> 
> [95% CI]
> -0.3 
> [-0.5, -0.1]<sup>c</sup>
> -0.6
> [-0.8, -0.4]<sup>c</sup>
> Patients (%) achieving HbA1c <7%
> 55
> 66
> 40”

Source: [OZEMPIC: Ozempic®, page 7, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=7)

> “The mean baseline body weight was 93.7 kg, 94 kg, 92.6 kg in the OZEMPIC<sup>®</sup> 0.5 mg, OZEMPIC<sup>®</sup> 
> 1 mg, and insulin glargine arms, respectively. The mean changes from baseline to week 30 were 
> -3.2 kg, -4.7 kg and 0.9 kg in the OZEMPIC<sup>®</sup> 0.5 mg, OZEMPIC<sup>®</sup> 1 mg, and insulin glargine arms, 
> respectively. The difference from insulin glargine (95% CI) for OZEMPIC<sup>®</sup> 0.5 mg was -4.1 kg 
> (-4.9, -3.3) and for OZEMPIC<sup>®</sup> 1 mg was -5.6 kg (-6.4, -4.8).”

Source: [OZEMPIC: Ozempic®, page 7, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=7)

> “SUSTAIN 4 was not designed to evaluate relative safety between Ozempic<sup>®</sup> injection and Lantus<sup>®</sup>”

Source: [OZEMPIC: A1C & Weight Results, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-pen-a1c-and-weight.html#:~:text=SUSTAIN%204%20was%20not%20designed,injection%20and)

> “Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 4% with Ozempic<sup>®</sup> injection 0.5 mg, 6% with Ozempic<sup>®</sup> injection 1 mg, and 11% with Lantus<sup>®5,a</sup>”

Source: [OZEMPIC: A1C & Weight Results, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-pen-a1c-and-weight.html#:~:text=Incidence%20of%20severe%20hypoglycemia%20or,1%20mg%2C%20and%2011%25%20with)

Note: Table columns are OZEMPIC® 0.5 mg, OZEMPIC® 1 mg, and insulin glargine, in that order; the difference-from-insulin-glargine row lists the 0.5 mg and 1 mg results. Table 6 of the Prescribing Information reports the 30-week trial of 1089 patients described on this page as SUSTAIN 4.

<a id="ozempic-sustain5-a1c"></a>

### How much did Ozempic lower A1C when added to basal insulin in SUSTAIN 5?

Applies to: Type 2 diabetes in adults; Ozempic injection (pen)

> “SUSTAIN 5: A 30-week, randomized, double-blind, placebo-controlled, parallel-group trial in 397 adult patients with type 2 diabetes evaluating the addition of Ozempic<sup>®</sup> injection 0.5 mg and Ozempic<sup>®</sup> injection 1 mg to basal insulin ± metformin. Patients with A1C ≤8% at screening had their background basal insulin dose reduced by 20% at the start of the trial to limit potential risk of hypoglycemia.<sup>1,6</sup>”

Source: [OZEMPIC: A1C & Weight Results, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-pen-a1c-and-weight.html#:~:text=SUSTAIN%205%3A%20A%2030%2Dweek%2C%20randomized%2C,to%20limit%20potential%20risk%20of)

On the page, select: Add-on to basal insulin

> “Table 8. Results at Week 30 in a Trial of OZEMPIC<sup>®</sup> in Adult Patients with Type 2 
> Diabetes Mellitus in Combination with Basal Insulin with or without Metformin
> Placebo
> OZEMPIC<sup>®</sup> 0.5 mg OZEMPIC<sup>®</sup> 1 mg
> Intent-to-Treat (ITT) Population (N)<sup>a</sup>
> 133
> 132
> 131
> HbA1c (%)
> Baseline (mean)
> 8.4
> 8.4
> 8.3
> Change at week 30<sup>b</sup>
> -0.2
> -1.3
> -1.7
> Difference from placebo<sup>b</sup> 
> [95% CI]
> -1.1 
> [-1.4, -0.8]<sup>c</sup>
> -1.6
> [-1.8, -1.3]<sup>c</sup>
> Patients (%) achieving HbA1c <7%
> 13
> 56
> 73”

Source: [OZEMPIC: Ozempic®, page 8, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=8)

> “The mean baseline body weight was 89.9 kg, 92.7 kg, and 92.5 kg in the placebo, OZEMPIC<sup>®</sup> 
> 0.5 mg, and OZEMPIC<sup>®</sup> 1 mg arms, respectively. The mean changes from baseline to week 30 
> were -1.2 kg, -3.5 kg, and -6 kg in the placebo, OZEMPIC<sup>®</sup> 0.5 mg, and OZEMPIC<sup>®</sup> 1 mg arms, 
> respectively. The difference from placebo (95% CI) for OZEMPIC<sup>®</sup> 0.5 mg was -2.2 kg (-3.4, 
> -1.1), and for OZEMPIC<sup>®</sup> 1 mg was -4.7 kg (-5.8, -3.6).”

Source: [OZEMPIC: Ozempic®, page 8, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=8)

> “Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was<sup>6</sup>:
> 8.3% with Ozempic<sup>®</sup> injection 0.5 mg + basal insulin ± MET
> 10.7% with Ozempic<sup>®</sup> injection 1 mg + basal insulin ± MET
> 5.3% with placebo + basal insulin ± MET”

Source: [OZEMPIC: Safety & Side Effects, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/safety-profile.html#:~:text=8.3%25%20with,placebo%20%2B%20basal%20insulin%20%C2%B1%20MET)

Note: Table columns are placebo, OZEMPIC® 0.5 mg, and OZEMPIC® 1 mg, in that order; the difference-from-placebo row lists the 0.5 mg and 1 mg results. Table 8 of the Prescribing Information reports the 30-week basal insulin trial of 397 patients described on this page as SUSTAIN 5.

<a id="ozempic-sustain-forte-a1c"></a>

### Does Ozempic 2 mg lower A1C more than Ozempic 1 mg (SUSTAIN FORTE)?

Applies to: Type 2 diabetes in adults; Ozempic injection (pen)

> “SUSTAIN FORTE: A 40-week, randomized, active-controlled trial in 961 adult patients with type 2 diabetes on metformin with or without a sulfonylurea, comparing Ozempic<sup>®</sup> injection 1 mg with Ozempic<sup>®</sup> injection 2  mg.<sup>1,3</sup>”

Source: [OZEMPIC: A1C & Weight Results, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-pen-a1c-and-weight.html#:~:text=SUSTAIN%20FORTE%3A%20A%2040%2Dweek%2C%20randomized%2C,injection%202)

> “Table 7. Results at Week 40 in a Trial of OZEMPIC<sup>®</sup> 2 mg Compared to OZEMPIC<sup>®</sup> 
> 1 mg in Adult Patients with Type 2 Diabetes Mellitus in Combination With 
> Metformin or Metformin with Sulfonylurea
> OZEMPIC<sup>®</sup> 1 mg
> OZEMPIC<sup>®</sup> 2 mg
> Intent-to-Treat (ITT) Population (N)<sup>a</sup>
> 481
> 480
> HbA1c (%)
> Baseline (mean)
> 8.8
> 8.9
> Change at week 40<sup>b</sup>
> -1.9
> -2.1
> Difference from OZEMPIC<sup>®</sup> 1 mg 
> [95% CI]
> -0.2
> [-0.31 ; -0.04]<sup>c</sup>
> Patients (%) achieving HbA1c <7%<sup>a</sup>
> 56
> 64”

Source: [OZEMPIC: Ozempic®, page 7, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=7)

> “The mean baseline body weight was 98.6 kg and 100.1 kg in the OZEMPIC<sup>®</sup> 1 mg and OZEMPIC<sup>®</sup> 
> 2 mg arms, respectively. The mean changes from baseline to week 40 were -5.6 kg and -6.4 kg in 
> the OZEMPIC<sup>®</sup> 1 mg and OZEMPIC<sup>®</sup> 2 mg arms, respectively. The difference between treatment 
> arms in body weight change from baseline at week 40 was not statistically significant.”

Source: [OZEMPIC: Ozempic®, page 7, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=7)

Note: Table columns are OZEMPIC® 1 mg and OZEMPIC® 2 mg, in that order.

<a id="ozempic-2mg-vs-mounjaro"></a>

### Ozempic 2 mg vs Mounjaro: is there a head-to-head trial?

Applies to: Type 2 diabetes in adults; Ozempic injection (pen)

> “There are no clinical trials evaluating Ozempic<sup>®</sup> 2 mg against Mounjaro<sup>®</sup> or other GLP-1 RAs”

Source: [OZEMPIC: ozempic-dosing-brochure.pdf, page 2, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/diabetes/products/resources/library/documents/ozempic-dosing-brochure.pdf#page=2)

Note: This is the manufacturer's statement in the Ozempic dosing brochure, as captured on November 12, 2026.

<a id="ozempic-pioneer4-a1c"></a>

### Ozempic pill vs liraglutide (Victoza): how much did each lower A1C (PIONEER 4)?

Applies to: Type 2 diabetes in adults; Ozempic tablets (pill)

> “PIONEER 4: In a double-blind, double-dummy trial with a primary endpoint of mean change in A1C from baseline to Week 26, 711 adult patients with type 2 diabetes receiving metformin alone or metformin with an SGLT-2i were randomized to semaglutide tablets 14 mg (n=285), liraglutide 1.8 mg subcutaneous injection (n=284), or placebo (n=142), all once daily.<sup>2</sup>”

Source: [OZEMPIC: A1C & Weight Results, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-pill-a1c-and-weight.html#:~:text=PIONEER%204%3A%20In%20a%20double%2Dblind%2C,or%20placebo%20%28n%3D142%29%2C%20all%20once)

> “Treatment with semaglutide tablets 14 mg once daily for 26 weeks resulted in statistically significant 
> reductions in HbA1c compared to placebo. Treatment with semaglutide tablets 14 mg once daily for 
> 26 weeks resulted in non-inferior reductions in HbA1c compared to liraglutide 1.8 mg (see Table 7).”

Source: [OZEMPIC: Ozempic®, page 8, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=8)

> “Table 7. Trial 4 Results at Week 26 in a Trial of Semaglutide Tablets Compared 
> to Liraglutide and Placebo in Adult Patients with Type 2 Diabetes Mellitus in 
> Combination with Metformin or Metformin with SGLT-2i
> Placebo
> Semaglutide 
> Tablets
> 14 mg
> Liraglutide
> 1.8 mg
> Intent-to-Treat (ITT) Population (N)<sup>a</sup>
> 142
> 285
> 284
> HbA1c (%)
> Baseline (mean)
> 7.9
> 8
> 8
> 	 Change at Week 26<sup>b</sup>
> -0.2
> -1.2
> -1.1
> 	 Difference from placebo<sup>b</sup> 
> [95% CI]
> -1.1 
> [-1.2; -0.9]<sup>c</sup>
> 	 Difference from liraglutide<sup>b</sup>
> [95% CI] 
> -0.1 
> [-0.3; 0]
> Patients (%) achieving HbA1c <7%
> 14
> 68
> 62”

Source: [OZEMPIC: Ozempic®, page 8, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=8)

> “The mean baseline body weight was 93.2 kg, 95.5 kg and 92.9 kg in the placebo, liraglutide 1.8 mg 
> and semaglutide tablets 14 mg arms, respectively. The mean changes from baseline to Week 26 were 
> -0.5 kg, -3.1 kg and -4.4 kg in the placebo, liraglutide 1.8 mg and semaglutide tablets 14 mg arms, 
> respectively. The difference from placebo (95% CI) for semaglutide tablets 14 mg was -3.8 kg (-4.7, 
> -3). The difference from liraglutide 1.8 mg for semaglutide tablets 14 mg was -1.2 (-1.9, -0.6).”

Source: [OZEMPIC: Ozempic®, page 8, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=8)

> “Ozempic<sup>®</sup> tablets 1.5 mg, 4 mg, and 9 mg are an updated formulation with increased bioavailability. This updated formulation is established with comparable mean exposure and peak concentration. The safety and effectiveness of Ozempic<sup>®</sup> tablets were established through adequate and well-controlled studies of semaglutide tablets 3 mg, 7 mg, and 14 mg.<sup>1,5</sup>”

Source: [OZEMPIC: A1C & Weight Results, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-pill-a1c-and-weight.html#:~:text=tablets%201.5%20mg%2C%204%20mg%2C,mg%2C%207%20mg%2C%20and%2014)

Note: Table columns are placebo, semaglutide tablets 14 mg, and liraglutide 1.8 mg, in that order. Trial 4 of the Prescribing Information has the same design and enrollment (711 patients) as PIONEER 4.

<a id="ozempic-pioneer2-a1c"></a>

### Ozempic pill vs empagliflozin (Jardiance): how much did each lower A1C (PIONEER 2)?

Applies to: Type 2 diabetes in adults; Ozempic tablets (pill)

> “PIONEER 2: In an open-label trial with a primary endpoint of mean change in A1C from baseline to Week 26, 822 adult patients with type 2 diabetes receiving metformin were randomized to semaglutide tablets 14 mg (n=412) or Jardiance<sup>®</sup> 25 mg (n=410), both once daily.<sup>3</sup>”

Source: [OZEMPIC: A1C & Weight Results, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-pill-a1c-and-weight.html#:~:text=PIONEER%202%3A%20In%20an%20open%2Dlabel,25%20mg%20%28n%3D410%29%2C%20both%20once)

On the page, select: vs Jardiance®

> “Table 5. Trial 2 Results at Week 26 in a Trial of Semaglutide Tablets Compared to 
> Empagliflozin in Adult Patients with Type 2 Diabetes Mellitus in Combination with 
> Metformin 
> Semaglutide Tablets
> 14 mg
> Empagliflozin
> 25 mg
> Intent-to-Treat (ITT) Population (N)<sup>a</sup>
> 411
> 410
> HbA1c (%)
> 	 Baseline (mean)
> 8.1
> 8.1
> 	 Change at Week 26<sup>b</sup>
> -1.3
> -0.9
> 	 Difference from empagliflozin<sup>b</sup> 
> [95% CI]
> -0.4 
> [-0.6, -0.3]<sup>c</sup>
> Patients (%) achieving HbA1c <7%
> 67
> 40”

Source: [OZEMPIC: Ozempic®, page 7, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=7)

> “The mean baseline body weight was 91.9 kg and 91.3 kg in the semaglutide tablets 14 mg and 
> empagliflozin 25 mg arms, respectively. The mean changes from baseline to Week 26 were -3.8 kg and 
> -3.7 kg in the semaglutide tablets 14 mg and empagliflozin 25 mg arms, respectively. The difference 
> from empagliflozin (95% CI) for semaglutide tablets 14 mg was -0.1 kg (-0.7, 0.5).”

Source: [OZEMPIC: Ozempic®, page 7, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=7)

> “Ozempic<sup>®</sup> tablets 1.5 mg, 4 mg, and 9 mg are an updated formulation with increased bioavailability. This updated formulation is established with comparable mean exposure and peak concentration. The safety and effectiveness of Ozempic<sup>®</sup> tablets were established through adequate and well-controlled studies of semaglutide tablets 3 mg, 7 mg, and 14 mg.<sup>1,5</sup>”

Source: [OZEMPIC: A1C & Weight Results, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-pill-a1c-and-weight.html#:~:text=tablets%201.5%20mg%2C%204%20mg%2C,mg%2C%207%20mg%2C%20and%2014)

Note: Table columns are semaglutide tablets 14 mg and empagliflozin 25 mg, in that order. This passage gives n=412 for semaglutide tablets 14 mg; the study design section of the same page and Table 5 of the Prescribing Information give 411. Trial 2 of the Prescribing Information has the same design and enrollment (822 patients) as PIONEER 2.

<a id="ozempic-pioneer3-a1c"></a>

### Ozempic pill vs sitagliptin (Januvia): how much did each lower A1C (PIONEER 3)?

Applies to: Type 2 diabetes in adults; Ozempic tablets (pill)

> “PIONEER 3: In a double-blind, double-dummy trial with a primary endpoint of mean change in A1C from baseline to Week 26, 1864 adult patients with type 2 diabetes receiving metformin alone or metformin with a sulfonylurea were randomized to semaglutide tablets 14 mg (n=465), 7 mg (n=466), 3 mg (n=466), or Januvia<sup>®</sup> 100 mg (n=467), all once daily.<sup>4</sup>”

Source: [OZEMPIC: A1C & Weight Results, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-pill-a1c-and-weight.html#:~:text=PIONEER%203%3A%20In%20a%20double%2Dblind%2C,100%20mg%20%28n%3D467%29%2C%20all%20once)

On the page, select: vs Januvia®

> “Table 6. Trial 3 Results at Week 26 in a Trial of Semaglutide Tablets Compared to 
> Sitagliptin 100 mg Once Daily in Adult Patients with Type 2 Diabetes Mellitus in 
> Combination with Metformin or Metformin with Sulfonylurea
> Semaglutide 
> Tablets
> 7 mg
> Semaglutide 
> Tablets
> 14 mg
> Sitagliptin
> 100 mg
> Intent-to-Treat (ITT) Population (N)<sup>a</sup>
> 465
> 465
> 467
> HbA1c (%)
> 	 Baseline (mean)
> 8.4
> 8.3
> 8.3
> 	 Change at Week 26<sup>b</sup>
> -1
> -1.3
> -0.8
> 	 Difference from sitagliptin<sup>b</sup>
> [95% CI]
> -0.3 
> [-0.4; -0.1]<sup>c</sup>
> -0.5 
> [-0.6; -0.4]<sup>c</sup>
> Patients (%) achieving HbA1c <7%
> 44
> 56
> 32”

Source: [OZEMPIC: Ozempic®, page 7, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=7)

> “The mean baseline body weight was 91.3 kg, 91.2 kg and 90.9 kg in the semaglutide tablets 7 mg, 
> semaglutide tablets 14 mg and sitagliptin 100 mg arms, respectively. The mean changes from baseline 
> to Week 26 were -2.2 kg, -3.1 kg and -0.6 kg in the semaglutide tablets 7 mg, semaglutide tablets 14 
> mg and sitagliptin 100 mg arms, respectively. The difference from sitagliptin (95% CI) for semaglutide 
> tablets 7 mg was -1.6 kg (-2.0, -1.1) and semaglutide tablets 14 mg was -2.5 kg (-3.0, -2.0).”

Source: [OZEMPIC: Ozempic®, page 8, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=8)

> “Ozempic<sup>®</sup> tablets 1.5 mg, 4 mg, and 9 mg are an updated formulation with increased bioavailability. This updated formulation is established with comparable mean exposure and peak concentration. The safety and effectiveness of Ozempic<sup>®</sup> tablets were established through adequate and well-controlled studies of semaglutide tablets 3 mg, 7 mg, and 14 mg.<sup>1,5</sup>”

Source: [OZEMPIC: A1C & Weight Results, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/efficacy-safety/ozempic-pill-a1c-and-weight.html#:~:text=tablets%201.5%20mg%2C%204%20mg%2C,mg%2C%207%20mg%2C%20and%2014)

Note: Table columns are semaglutide tablets 7 mg, semaglutide tablets 14 mg, and sitagliptin 100 mg, in that order. This passage gives n=466 for semaglutide tablets 7 mg; the study design section of the same page and Table 6 of the Prescribing Information give 465. Trial 3 of the Prescribing Information has the same design and enrollment (1864 patients) as PIONEER 3.

## Cardiovascular outcomes

<a id="ozempic-sustain6-mace"></a>

### Does Ozempic lower the risk of heart attack, stroke, and cardiovascular death (SUSTAIN 6)?

Applies to: Adults with type 2 diabetes and established cardiovascular disease; Ozempic injection

> “SUSTAIN 6: A 2-year CVOT for Ozempic<sup>®</sup> injection<sup>1,2</sup>
>
> A 109-week, multicenter, multinational, placebo-controlled, double-blind CVOT in 3297 adult patients with inadequately controlled T2D and atherosclerotic cardiovascular disease. Patients had a mean duration of diabetes of 13.9 years and a mean baseline A1C of 8.7%, and 58% were taking insulin.”

Source: [OZEMPIC: Cardiovascular Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/cv-outcomes/pen.html#:~:text=SUSTAIN%206%3A%20A%202%2Dyear%20CVOT,and%2058%25%20were%20taking%20insulin.)

> “Overall MACE occurred in 108 patients of 1648 (6.6%) on Ozempic<sup>®</sup> injection (0.5 mg and 1 mg) and 146 patients of 1649 (8.9%) on placebo (HR, 0.74 [95% CI: 0.58-0.95] P<0.001 for noninferiority, P=0.02 for superiority, not prespecified); nonfatal stroke occurred in 27 patients (1.6%) on Ozempic<sup>®</sup> injection and 44 patients (2.7%) on placebo; nonfatal MI occurred in 47 patients (2.9%) on Ozempic<sup>®</sup> injection and 64 patients (3.9%) on placebo; CV death occurred in 44 patients (2.7%) on Ozempic<sup>®</sup> injection and 46 patients (2.8%) on placebo.<sup>1,2</sup>”

Source: [OZEMPIC: Cardiovascular Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/cv-outcomes/pen.html#:~:text=Overall%20MACE%20occurred%20in%20108,and%2046%20patients%20%282.8%25%29%20on)

> “This study was not powered to detect a difference in the individual endpoints of the composite MACE. Absolute rates for the combined endpoint of “fatal or nonfatal stroke”: 1.8% (n=30 of 1648) with Ozempic<sup>®</sup> injection and 2.8% (n=46 of 1649) with placebo. HR, 0.65 (95% CI: 0.41-1.03); P=NS. There was no significant change in the rate of nonfatal MI or CV death.<sup>1,2,r</sup>”

Source: [OZEMPIC: Cardiovascular Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/cv-outcomes/pen.html#:~:text=This%20study%20was%20not%20powered,of%20nonfatal%20MI%20or%20CV)

> “Estimated cumulative risk of MACE at Week 104 was 6.2% with Ozempic<sup>®</sup> pen 0.5 mg and 1 mg and 8.4% with placebo.<sup>3</sup>”

Source: [OZEMPIC: Cardiovascular Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/cv-outcomes/pen.html#:~:text=cumulative%20risk%20of%20MACE%20at,1%20mg%20and%208.4%25%20with)

<a id="ozempic-soul-mace"></a>

### Does the Ozempic pill lower the risk of heart attack, stroke, and cardiovascular death (SOUL)?

Applies to: Adults with type 2 diabetes at high risk for major cardiovascular events; semaglutide tablets

> “SOUL evaluated cardiovascular outcomes with semaglutide tablets once daily in adults with T2D with CVD and/or CKD<sup>7,8</sup>
>
> A randomized, international, double-blind, parallel-group, placebo-controlled, event-driven, superiority CVOT.<sup>7,8</sup>
>
> At baseline, patients had a mean A1C of 8.0%, 71% had CAD, 21% had CeVD, 16% had PAD, and 13% had CKD.<sup>7,8</sup>
>
> At baseline, 97% were treated with one or more glucose-lowering medications: metformin (76%), insulin (51%), SGLT-2 inhibitor (27%), sulfonylurea (29%), and DPP-4 inhibitors (23%); 89% were taking lipid-lowering medications including platelet-aggregation inhibitors (77%), ACE inhibitors or angiotensin receptor blockers (79%), and beta-blockers (64%).<sup>7,8</sup>
>
> Mean duration of follow-up was 47.5±10.9 months.<sup>7,8</sup>”

Source: [OZEMPIC: Cardiovascular Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/cv-outcomes/pill.html#:~:text=SOUL%20evaluated%20cardiovascular%20outcomes%20with,duration%20of%20follow%2Dup%20was%2047.5%C2%B110.9)

> “Semaglutide tablets significantly reduced the occurrence of MACE. The estimated hazard ratio for 
> time to first MACE was 0.86 (95% CI: 0.77, 0.96) over the median follow-up duration of 49.6 months 
> and 49.4 months for patients randomized to RYBELSUS<sup>®</sup> and placebo, respectively.”

Source: [OZEMPIC: Ozempic®, page 8, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=8)

> “Table 10. Trial 7 Treatment Effect for MACE and its Components
> Placebo 
> N=4,825
> Semaglutide 
> Tablets 14 mg 
> N=4,825
> Hazard Ratio 
> vs Placebo 
> (95% CI)
> Primary composite endpoint
> MACE: Composite of CV death, non-fatal MI, 
> non-fatal stroke (time to first occurrence)
> 668 (13.8%)
> 579 (12%)
> 0.86 (0.77, 0.96)
> CV death
> 320 (6.6%)
> 301 (6.2%)
> 0.93 (0.8, 1.09)
> Non-fatal MI
> 253 (5.2%)
> 191 (4%)
> 0.74 (0.61, 0.89)
> Non-fatal stroke
> 161 (3.3%)
> 144 (3%)
> 0.88 (0.7, 1.11)”

Source: [OZEMPIC: Ozempic®, page 9, captured 2026-11-12](https://www.novo-pi.com/ozempictablets.pdf#page=9)

> “In a prespecified analysis of primary-outcome events occurring through Week 156 (3 years), the absolute risk reduction was 2%, and the number needed to treat to prevent one event in this population was 50 persons (95% CI: 31-125).<sup>8</sup>”

Source: [OZEMPIC: Cardiovascular Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/cv-outcomes/pill.html#:~:text=a%20prespecified%20analysis%20of%20primary%2Doutcome,was%2050%20persons%20%2895%25%20CI%3A)

> “Ozempic<sup>®</sup> tablets 1.5 mg, 4 mg, 9 mg are an updated formulation with increased bioavailability. This updated formulation is established with comparable mean exposure and peak concentration. The safety and effectiveness of Ozempic<sup>®</sup> tablets were established through adequate and well-controlled studies of semaglutide tablets 3 mg, 7 mg, 14 mg.<sup>7,9</sup>”

Source: [OZEMPIC: Cardiovascular Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/cv-outcomes/pill.html#:~:text=tablets%201.5%20mg%2C%204%20mg%2C,3%20mg%2C%207%20mg%2C%2014)

Note: Table 10 rows list placebo events, semaglutide tablets 14 mg events, and the hazard ratio (95% CI), in that order. Trial 7 of the Prescribing Information has the same design and enrollment (9,650 patients) as SOUL.

## Kidney outcomes

<a id="ozempic-flow-kidney"></a>

### Does Ozempic slow kidney disease progression in type 2 diabetes and CKD (FLOW)?

Applies to: Adults with type 2 diabetes and chronic kidney disease; Ozempic injection

> “A randomized, double-blind, placebo-controlled, event-driven trial that followed 3533 patients with type 2 diabetes and chronic kidney disease (eGFR 25 to 75 mL/min/1.73 m<sup>2</sup> with UACR >100 mg/g and <5000 mg/g) for a median follow-up of 41 months.<sup>1,2</sup>
>
> At baseline, patients had a mean eGFR of 47 mL/min/1.73 m<sup>2</sup> and a median UACR of 568 mg/g (11% of patients had an eGFR <30 mL/min/1.73 m<sup>2</sup> and 69% of patients with UACR >300 mg/g at baseline).<sup>1,2</sup>”

Source: [OZEMPIC: Chronic Kidney Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/ckd-outcomes.html#:~:text=A%20randomized%2C%20double%2Dblind%2C%20placebo%2Dcontrolled%2C%20event%2Ddriven,with%20UACR%20%3E300%20mg%2Fg%20at)

> “Overall, the primary composite endpoint occurred in 331 patients of 1767 (18.7%) on Ozempic<sup>®</sup> (1 mg) and 410 patients of 1766 (23.2%) on placebo (HR, 0.76 [95% CI: 0.66-0.88] P=0.0001 for superiority).<sup>1</sup>
>
> ≥50% sustained eGFR decline occurred in 165 patients (9.3%) on Ozempic<sup>®</sup> and 213 patients (12.1%) on placebo. Sustained eGFR <15 mL/min/1.73 m<sup>2</sup> occurred in 92 patients (5.2%) on Ozempic<sup>®</sup> and 110 patients (6.2%) on placebo. Chronic renal replacement therapy occurred in 87 patients (4.9%) on Ozempic<sup>®</sup> and 100 patients (5.7%) on placebo. Renal death occurred in 5 patients (0.3%) on Ozempic<sup>®</sup> and 5 patients (0.3%) on placebo. CV death occurred in 123 patients (7.0%) on Ozempic<sup>®</sup> and 169 patients (9.6%) on placebo.<sup>1</sup>”

Source: [OZEMPIC: Chronic Kidney Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/ckd-outcomes.html#:~:text=Overall%2C%20the%20primary%20composite%20endpoint,and%20169%20patients%20%289.6%25%29%20on)

> “4.9% ARR reported at 3 years in prespecified supplementary analysis.”

Source: [OZEMPIC: Chronic Kidney Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/ckd-outcomes.html#:~:text=ARR%20reported%20at%203%20years%20in%20prespecified%20supplementary%20analysis.)

> “The treatment effect on the primary composite endpoint was generally consistent across the 
> pre-specified subgroups examined, including age, biological sex, eGFR and UACR. The treatment 
> benefit on the primary composite endpoint was not evident in patients taking SGLT2 inhibitors at 
> baseline, but there were few events in these patients.”

Source: [OZEMPIC: Ozempic®, page 8, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=8)

Note: On the CKD outcomes page, the 4.9% ARR footnote accompanies the primary composite endpoint result. The linked Ozempic® injection Prescribing Information (section 14.3) reports p=0.0003 for the primary composite endpoint.

<a id="ozempic-flow-mace-death"></a>

### Does Ozempic lower cardiovascular events and death in type 2 diabetes with CKD (FLOW)?

Applies to: Adults with type 2 diabetes and chronic kidney disease; Ozempic injection

> “OZEMPIC<sup>®</sup> also reduced the annual rate of change in eGFR (Figure 9), the incidence of a composite 
> cardiovascular endpoint, consisting of non-fatal myocardial infarction (MI), non-fatal stroke, and 
> cardiovascular death, and the incidence of all-cause death (Table 10 and Figure 8).”

Source: [OZEMPIC: Ozempic®, page 8, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=8)

> “Table 10: Analyses of the Primary and Secondary Endpoints and their Individual 
> Components in FLOW Trial
> Placebo 
> N=1766 (%)
> OZEMPIC<sup>®</sup> 
> 1 mg 
> N=1767 (%)
> Hazard Ratio 
> vs Placebo
> (95% CI)<sup>1</sup>
> p-value<sup>2</sup>”

Source: [OZEMPIC: Ozempic®, page 8, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=8)

> “Composite of cardiovascular death, 
> non-fatal myocardial infarction, 
> non-fatal stroke (time to first 
> occurrence)
> 254 (14.4)
> 212 (12)
> 0.82 (0.68, 0.98)
> 0.0289
> All-cause death
> 279 (15.8)
> 227 (12.8)
> 0.8 (0.67, 0.95)
> 0.0104”

Source: [OZEMPIC: Ozempic®, page 8, captured 2026-11-12](https://www.novo-pi.com/ozempic.pdf#page=8)

> “2.2% ARR reported at 3 years in a prespecified supplementary analysis.”

Source: [OZEMPIC: Chronic Kidney Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/ckd-outcomes.html#:~:text=ARR%20reported%20at%203%20years%20in%20a%20prespecified%20supplementary%20analysis.)

> “2.5% ARR reported at 3 years in pre-specified supplementary analysis.”

Source: [OZEMPIC: Chronic Kidney Disease, captured 2026-11-12](https://www.novomedlink.com/diabetes/products/treatments/ozempic/ckd-outcomes.html#:~:text=ARR%20reported%20at%203%20years%20in%20pre%2Dspecified%20supplementary%20analysis.)

On the page, select: Time of first occurrence of all-cause mortality

Note: Table 10 rows list placebo, OZEMPIC® 1 mg, the hazard ratio (95% CI), and the p-value, in that order. On the CKD outcomes page, the 2.2% ARR footnote accompanies the MACE result and the 2.5% ARR footnote accompanies the all-cause mortality result.

## Related pages
- [Medical information: Ozempic (semaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ozempic--type-2-diabetes/access-and-coverage)
